Modern view on the use of alpha lipoic acid in neurological practice
Open Access
- 10 May 2024
- journal article
- review article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 70-81
Abstract
Alpha lipoic acid (ALA) is an essential cofactor for mitochondrial enzymes, a powerful antioxidant, and an important component of many metabolic processes. Most research on ALA has focused specifically on its antioxidant properties. A number of conditions – aging, atherosclerosis, liver cirrhosis, diabetes mellitus, various types of polyneuropathy, psoriasis and others can significantly reduce the level of ALA in the body. The article analyzes modern literature (107 sources, including 17 systematic reviews and meta-analyses). Traditionally, ALA is used in complex therapy of patients suffering from diabetic and alcoholic polyneuropathy. However, the analysis of studies conducted around the world is not limited to these two nosological forms. The use of ALA as adjuvant therapy for a number of conditions and diseases is justified, as confirmed by clinical studies, systematic reviews and meta-analyses. All studies assessed not only the effectiveness of ALC, but also its safety and the incidence of adverse events and showed that ALC has a high safety profile. ALA has not only a pronounced antioxidant effect, but also the ability to chelate toxic metals, increase intracellular glutathione levels, reduce blood glucose levels, overcome insulin resistance, participate in mitochondrial metabolism, stimulate the production of cAMP, normalize the lipid profile, reduce the level of inflammatory markers, etc. Based on Because of the positive effect of using ALC in the treatment of various symptoms and nosologies, the list of indications requires revision, expansion and addition.Keywords
This publication has 96 references indexed in Scilit:
- Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafishMuscle & Nerve, 2024
- Alpha-lipoic acid for diabetic peripheral neuropathyCochrane Database of Systematic Reviews, 2024
- Coenzyme Q10 + alpha lipoic acid for chronic COVID syndromeClinical and Experimental Medicine, 2022
- Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patientsSupportive Care in Cancer, 2022
- The role of biofactors in the prevention and treatment of age‐related diseasesBioFactors, 2021
- Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumoniaInflammation Research, 2020
- Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potentialInflammation Research, 2017
- ?-Lipoic acid-based PPAR? agonists for treating inflammatory skin diseasesArchives of Dermatological Research, 2004
- Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant ?-lipoic acidDiabetologia, 1995
- The Chemistry and Function of Lipoic Acid1957